natgillin/translations-raw huggingface dataset:
A stable injectable noradrenaline solution with an amount of preservatives and/or anti-oxidizing agents lower than 0.005% by weight, wherein solvent is degassed or deaerated water, the concentration of noradrenaline is in the range from 0.04 to 0.2 mg/ml and pH is from 3.2 to 3.6 by hydrochloric acid. 
Stabilna, injektabilna otopina noradrenalina s količinom konzervansa i/ili antioksidacijskih sredstava nižom od 0.005 težinskih %, pri čemu je otapalo otplinjena ili deaerirana voda, koncentracija noradrenalina je u opsegu od 0.04 do 0.2 mg/ml i pH je od 3.2 do 3.6 pomoću klorovodične kiseline.
A noradrenaline stable injectable solution according to claim 12, wherein the excipient is sodium chloride. 
Stabilna, injektabilna otopina noradrenalina prema patentnom zahtjevu 12, naznačena time što je ekscipijens natrijev klorid.
at least two stiffening pipes (12) disposed through the ribs (14); 
najmanje dvije cijevi za ukrućenje (12) postavljene kroz rebra (14);
A fish farming plant (1), adapted for floating in free water, comprising: an inlet pipe (3) for supplying water; 
Postrojenje za uzgoj ribe (1), prilagođeno za plutanje u slobodnoj vodi, naznačeno time da obuhvaća: ulaznu cijev (3) za dovod vode;
at least one means for providing water flow through the residential compartment (30); 
barem jedno sredstvo za osiguravanje strujanja vode kroz stambeni odjeljak (30);
at least one barrier lattice (7) at the inlet end of the residential compartment (30); 
barem jednu rešetkastu prepreku (7) na ulaznom kraju stambenog odjeljka (30);
an outlet pipe (4) for discharging water; 
izlaznu cijev (4) za ispuštanje vode;
at least four ballastable buoyancy tanks which can be selectively emptied or filled in order to lift, lower, or tilt said fish farming plant (1); 
najmanje četiri balastna uzgonska spremnika koji se mogu selektivno prazniti ili puniti kako bi se navedeno postrojenje za uzgoj ribe (1) podizalo, spuštalo ili naginjalo;
The fish farming plant (1) of claim 3, further comprising: a first means for providing water flow in the first end section and a second means for providing water flow in the second end section. 
Postrojenje za uzgoj ribe (1) prema zahtjevu 3, naznačeno time da dodatno sadrži: prvo sredstvo za osiguranje strujanja vode u prvom kraju i a drugo sredstvo za osiguranje strujanja vode u drugom kraju odjeljka.
The fish farming plant (1) of claim 3, further comprising at least one water pump for emptying the buoyancy tanks. 
Postrojenje za uzgoj ribe (1) prema zahtjevu 3, naznačeno time da dodatno sadrži najmanje jednu pumpu za vodu za pražnjenje uzgonskih spremnika.
The fish farming plant (1) of claim 3, wherein the residential compartment (30) has a volume in the range of 6000 m3 to 20,000 m3. 
Postrojenje za uzgoj ribe (1) prema zahtjevu 3, naznačeno time da stambeni odjeljak (30) ima volumen u rasponu od 6000 m3 do 20,000 m3.
The fish farming plant (1) of claim 3, wherein the length of the inlet pipe (3) and the outlet pipe (4) is adapted so that water is taken from a depth (h) of 30 meters. 
Postrojenje za uzgoj ribe (1) prema zahtjevu 3, naznačeno time da je duljina ulazne cijevi (3) i izlazne cijevi (4) prilagođena tako da se voda uzima iz dubine (h) od 30 metara.
A residential compartment for a fish farming plant (1) composed of at least two polyethylene modules according to claim 2, welded together through plastic welding. 
Stambeni odjeljak postrojenja za uzgoj ribe (1) naznačen time da je sastavljen od najmanje dva polietilenska modula prema zahtjevu 2, međusobno zavarena pomoću zavarivanja plastike.
A method for manufacturing a residential compartment (2) for a fish farming plant (1) comprised of polyethylene modules according to claim 2, comprising plastic welding the individual modules to each other in an end-to-end relation until an elongate oval residential compartment (30) including a number of modules as determined by the desired capacity for the fish farming plant (1) has been formed. 
Postupak za proizvodnju stambenog odjeljka (2) za postrojenje za uzgoj ribe (1) sastavljeno od polietilenskih modula prema zahtjevu 2, naznačen time da obuhvaća međusobno plastično zavarivanje pojedinačnih modula u odnosu od kraja do kraja sve do oblikovanja produljenog izduženog ovalnog stambenog odjeljka (30) koji uključuje veći broj modula koji su određeni željenim kapacitetom postrojenja za uzgoj ribe (1).
Use of a fish farming plant (1) according to claim 3 for smolt. 
Uporaba postrojenja za uzgoj ribe (1) prema zahtjevu 3 naznačena time da je za mlade ribe.
A method for emptying a fish farming plant (1) according to claim 3, comprising tilting the fish farming plant (1) through emptying at least one of the ballastable buoyancy tanks in order to concentrate the species being farmed in an end of the residential compartment (30). 
Postupak za pražnjenje postrojenja za uzgoj ribe (1) prema zahtjevu 3, naznačen time da obuhvaća naginjanje postrojenja za uzgoj ribe (1) pražnjenjem barem jednog od balastnih uzgonskih spremnika da bi se vrste koje se uzgajaju koncentrirale na kraju stambenog odjeljka (30).
A nucleic acid encoding an immunoglobulin heavy chain with retained genomic exon-intron organization comprising a nucleic acid encoding the amino acid sequence of the C-terminal part of the CH3-domain of an immunoglobulin of the class IgG, characterized in that the glycine-lysine-dipeptide at the C-terminus in said amino acid sequence of the C-terminal part of the CH3-domain is encoded by the nucleic acid ggcaaa. 
Nukleinska kiselina koja kodira teški lanac imunoglobulina sa zadržanom genomskom organizacijom eksona-introna koja obuhvaća nukleinsku kiselinu koja kodira sekvencu aminokiseline iz C-terminalnog dijela CH3-domene imunoglobulina razreda IgG, naznačena time, da glicin-lizin-dipeptid na C-terminusu u navedenoj sekvenci aminokiseline iz C-terminalnog dijela CH3-domene, kodira nukleinska kiselina ggcaaa.
A nucleic acid according to claim 1, characterized in that the nucleic acid encoding said glycine-lysine-dipeptide is preceded by the nucleotide g or a. 
Nukleinska kiselina prema patentnom zahtjevu 1, naznačena time, da nukleinskoj kiselini koja kodira navedeni glicin-lizin-dipeptid, prethodi nukleotid g ili a.
A nucleic acid according to claim 1, characterized in that said nucleic acid encoding the amino acid sequence of the C-terminal part of the CH3-domain of an immunoglobulin of the class IgG is selected from the nucleic acids of SEQ ID NO: 20, 23, or 30. 
Nukleinska kiselina prema patentnom zahtjevu 1, naznačena time, da je navedena nukleinska kiselina koja kodira sekvencu aminokiseline iz C-terminalnog dijela CH3-domene imunoglobulina razreda IgG, odabrana iz skupine koju čine nukleinske kiseline iz ID BR. SEK: 20, 23 ili 30.
A nucleic acid according to any one of the preceding claims, wherein the immunoglobulin heavy chain is from human IgG1 subclass with mutations L234A and L235A. 
Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da je teški lanac imunoglobulina iz humanog podrazreda IgG1 s mutacijama L234A i L235A.
transfecting said mammalian cell with a nucleic acid encoding an immunoglobulin heavy chain according to claim 3, 
transfekciju navedene stanice sisavaca s nukleinskom kiselinom koja kodira teški lanac imunoglobulina prema patentnom zahtjevu 3,
cultivating the transfected mammalian cell under conditions suitable for the expression of the immunoglobulin, 
kultiviranje transficirane stanice sisavaca pod uvjetima pogodnima za ekspresiju imunoglobulina,
recovering the immunoglobulin from the culture or the cell. 
oporavljanje imunoglobulina iz kulture ili stanice.
Method according to claim 9, characterized in that said mammalian cell is transfected with one nucleic acid comprising an expression cassette encoding an immunoglobulin heavy chain and an expression cassette encoding an immunoglobulin light chain. 
Postupak prema patentnom zahtjevu 9, naznačen time, da se navedena stanica sisavaca transficira s jednom nukleinskom kiselinom koja obuhvaća jednu kazetu za ekspresiju koja kodira teški lanac imunoglobulina i jednu kazetu za ekspresiju koja kodira laki lanac imunoglobulina.
A compound having Formula (IVa-2): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: 
Spoj koji ima Formulu (IVa-2): [image] ili njegova farmaceutski prihvatljiva sol, solvat, tautomer, stereoizomer, ili deuterirani analog, naznačen time da:
or the two adjacent R9 substituents on an aromatic ring are taken together to form a 5 or 6-membered ring having from 0-2 heteroatoms selected from O, N, and S; 
ili dva susjedna R9 supstituenta na aromatskom prstenu su uzeti zajedno da tvore 5 ili 6-čalni prsten koji ima 0-2 heteroatoma odabrani od O, N, i S;
A compound as defined in any of claims 1-14, for use in the treatment of melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical cancer, prostate cancer, histiocytic lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, acute pain, chronic pain, or polycystic kidney disease. 
Spoj kako je definiran u bilo kojem od zahtjeva 1-14, naznačen time da je za uporabu za liječenje melanoma, glioma, glioblastoma multiforme, pilocitnog astrocitoma, sarkoma, raka jetre, raka žučnog trakta, kolangiokarcinoma, raka debelog crijeva, raka pluća, raka žučnog mjehura, raka dojke, raka gušterače, raka štitnjače, raka bubrega, rak jajnika, raka nadbubrežne žlijezde, rak prostate, histiocitnog limfoma, neurofibromatoze, gastrointestinalnih stromalnih tumora, akutne mijeloidne leukemije, mijelodisplastičnog sindroma, leukemije, tumorske angiogeneze, medularnog karcinoma štitnjače, karcinoida, raka pluća malih stanica, Kaposijevog sarkoma, feokromocitoma, akutne boli, kronične boli, ili policistične bolesti bubrega.
The antibody or antibody fragment according to claim 12, wherein the disease is selected from the group consisting of an allergic disease, asthma, cancer, an autoimmune disease, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
Use of the antibody or antibody fragment of any one of claims 1 to 5 in research or in vitro diagnostic applications, wherein said antibody or antibody fragment comprises a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
The pharmaceutical kit in accordance with claim 9, wherein the second compartment comprises the disodium salt form of the compound N -[4-[2-(2-amino-4,7-dihydro-4-oxo-1 H -pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid. 
Spoj za uporabu prema zahtjevu 8 ili 9, naznačen time, da farmaceutski prihvatljiva soli spoja N-[4-[2-(2-amino-4,7-dihidro-4-okso-1H-pirolo[2,3-d]pirimidin-5-il)etil]benzoil]-L-glutaminske kiseline, predstavlja njegovu dinatrijevu sol.
A pharmaceutical composition according to claim 4, including at least one pharmaceutically acceptable excipient. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time, da obuhvaća i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo.
The pharmaceutical composition according to claim 1, comprising said Form II of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and said excipient in a ratio of about 1:8 by weight. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time da sadrži navedenu 1-[3-(4-bromo-2-metil-2H-pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-ureu i navedenu pomoćnu tvar u omjeru od oko 1:8 po masi.
said excipient in an amount of about 40% by weight of the total composition; and 
navedenu pomoćnu tvar u količini od oko 40 masenih % cjelokupnog pripravka; i
An autonomous firefighting agent (10) of claim 1, wherein the halocarbon is enclosed in a polymeric shell of polyurea and/or polyurethane on the basis of polyisocyanate prepolymer. 
Autonomni protupožarni agens (10) prema zahtjevu 1, naznačen time, da je halogeni ugljikovodik zatvoren polimernoj ovojnici poliuree i/ili poliuretana na osnovi poliizocijanatnog predpolimera.
An autonomous firefighting agent (10) of claim 1 or claim 2, wherein the halocarbon is selected from one of the following first substances: (a) 1,1,2,2-tetrafluorodibromoethane; (b) 1,1,2-trifluorotrichloroethane; and (c) 2-iodo-1,1,1,2,3,3,3-heptafluoropropane, and/or a mixture thereof with other halocarbons. 
Autonomni protupožarni agens (10) prema zahtjevu 1 ili 2, naznačen time, da je halogeni ugljikovodik odabran iz jedne od sljedećih prvih supstanci: (a) 1,1,2,2-tetraflorodibrometana; (b) 1,1,2-triflorotrikloretana; i (c) 2-jodo-l, l, l, 2,3,3,3-heptafloropropana i/ili njihove mješavine s ostalim halogenim ugljikovodicima.
preparing (101) a first mixture of a fire-extinguishing agent and polyisocyanate; 
pripremu (101) prve smjesu sredstva za gašenje požara i poliizocijanata;
obtaining (102) an emulsion of the first mixture in an aqueous solution of polyvinyl alcohol; 
dobivanje (102) emulzije prve smjese u vodenoj otopini polivinilnog alkohola;
adding (1020) the resulting emulsion to an aqueous solution of polyethylene polyamine; 
dodavanje (1020) rezultirajuće emulzije u vodenu otopinu polietilenog poliamina;
producing (103) a suspension of microcapsules in water; 
proizvodnju (103) suspenzije mikrokapsule u vodi;
preparing (104) a second mixture of the suspension and a binder; 
priprema (104) drugu smjesu suspenzije i veziva;
shaping (1040) the second mixture into plates; 
oblikovanje (1040) druge mješavine u ploče;
applying (107) an adhesive layer (6) to one side of a plate; 
nanošenje (107) ljepljivog sloja (6) na jednu stranu ploče;
covering (108) the adhesive layer with a detachable protective film (7); and 
pokrivanje (108) ljepljivog sloja s odvojivim zaštitnim filmom (7); i
cutting up (106) the plates into pieces of desired size. 
rezanje (106) ploča na komade željene veličine.
each of R3 and R4 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy, NR9R10, wherein R9 and R10 independently are hydrogen or C1-C4 alkyl; or the two R3 groups taken together form a six membered heterocyclic ring containing a nitrogen atom; 
i R4je neovisno odabran iz skupine koju čine vodik, halogen, C1-C4 alkil, difluormetil, trifluormetil, C1-C4 alkiloksi, NR9R10, gdje su R9 i R10 neovisno vodik ili C1-C4 alkil, ili 2-tiazolidin-1,1-dion; ili dvije R3 skupine ili R3 i R4 skupine uzete zajedno tvore šesteročlani heterociklički prsten koji sadrži dušikov atom;
is selected from hydrogen, halogen, or is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen, C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy; is hydrogen or C1-C4 alkyl; the radical represents an optionally substituted piperidine, morpholine or 1,2,3,4-tetrahydroisoquinoline ring, wherein each of R6 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, difluoromethyl, trifluoromethyl, C1-C4 alkyloxy, or C1-C4 aryloxy or C1-C4 arylalkoxy wherein the aryl group is optionally substituted with halogen C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy. 
je odabran od vodika, halogena, ili je heterociklički prsten odabran od pirimidin-2-il, piridin-2-il ili pirazin-2-il, koji može biti supstituiran halogenom, C1-C4 alkilom, fluormetilom, difluormetilom, trifluormetilom ili C1-C4 alkiloksi; R7je vodik ili C1-C4 alkil; radikal predstavlja azetidin, pirolidin, piperidin, morfolin, oksazepan ili 1,2,3,4-tetrahidroizokinolin prsten koji može biti supstituiran, gdje je svaki od R6 neovisno odabran iz skupine koju čine vodik, halogen, C1-C4 alkil, C3-C6 cikloalkil, C3-C6 spirocikloalkil, difluormetil, trifluormetil, C1-C4 alkiloksi, aril, heteroaril, C1-C4 ariloksi ili C1-C4 arilalkoksi gdje arilna skupina ili heteroarilna skupina može biti supstituirana halogenom, C1-C4 alkilom, fluormetilom, difluormetilom, trifluormetilom ili C1-C4 alkiloksi.
A compound of Formula (I) according to claims 1- 4 wherein R4 is hydrogen, the R3 in meta position is hydrogen and the R3 in ortho position is selected from the group consisting of halogen, or C1-C4 alkyl, and R5 is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen. 
Spoj formule (I) prema patentnim zahtjevima 1-4 naznačeno time da je R4 vodik, R3 u meta-položaju jest vodik a R3 u ortho-položaju odabran je iz skupine koju čine halogen, ili C1-C4 alkil, a R5 je heterociklički prsten odabran od pirimidin-2-il, piridin-2-il ili pirazin-2-il, koji može biti supstituiran halogenom.
A compound of Formula (I) according to claims 1-8 for use in prevention and/or treatment of neurodegenerative, cognitive, psychiatric disorders, neuropathic pain, chronic pain, inflammatory processes of the muscular-skeletal system, liver fibrosis, gastrointestinal tract disorders, genitor-urinary tract disorders, ophthalmic diseases, Chronic Obstructive Pulmonary Disease (COPD), cancer and proliferative diseases. 
Spoj formule (I) prema patentnim zahtjevima 1-7 za upotrebu u sprječavanju i/ili liječenju neurodegenerativnih, kognitivnih, psihijatrijskih poremećaja, neoropatske boli, kronične boli, neuroinflamacije izazvane HIV-om te oštećenja CNS, epilepsije, upalnih procesa mišićno-koštanog sustava, fibroze jetre, poremećaja gastrointestinalnog trakta, poremećaja genito-urinarnog trakta, oftalmičnih bolesti, kronične opstruktivne plućne bolesti (COPD), karcinoma i proliferativnih bolesti.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria to reduce the number of nocturnal voids in a female patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg for administration prior to bedtime, wherein the dose is measured as the free base of desmopressin. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja muškog pacijenta koji ima nokturiju ili noćnu poliuriju, za smanjenje broja noćnih pražnjenja mjehura kod muškog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina od 25 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.
A composition comprising desmopressin for use in treating a female patient having nocturia or nocturnal polyuria, by reducing nocturnal urine volume in the female patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg for administration prior to bedtime, wherein the dose is measured as the free base of desmopressin. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja muškog pacijenta koji ima nokturiju ili noćnu poliuriju, za smanjenje broja noćnih pražnjenja mjehura kod muškog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina od 25 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.
The D2, D3, or D4 dopamine receptor agonist and the chemical compound having sedative effects for use as set forth in claim 1, wherein the dopamine agonist is administered in a pill, orally in a liquid form, intravenously in a liquid form, using a transdermal patch, or by inhalation, and wherein the chemical compound that is a sedative is administered in a pill, orally in a liquid form, intravenously in a liquid form, using a transdermal patch, or by inhalation. A product comprising: 
Agonist dopaminskog receptora D2, D3 ili D4 i kemijski spoj sedativnog djelovanja, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što dopaminski agonist se primjenjuje u piluli, oralno u obliku tekućine, intravenski u obliku tekućine, upotrebom transdermalnog flastera ili inhaliranjem, te što se kemijski spoj koji je sedativ primjenjuje u piluli, oralno u obliku tekućine, intravenski u obliku tekućine, upotrebom transdermalnog flastera ili inhaliranjem.
A product for use as set forth in claim 6 comprising a form which is capable of administration to an individual as a pill and wherein compound A and compound B are separately placed within the pill. 
Proizvod, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je u obliku kojeg se može primijeniti na osobi u obliku pilule, te što su gdje spoj A i spoj B odvojeno smješteni unutar pilule.
A product for use as set forth in claim 6 comprising a form which is capable of administration to an individual as a pill and wherein compound A and compound B are combined within the pill. 
Proizvod, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je u obliku kojeg se može primijeniti na osobi u obliku pilule, te što su gdje spoj A i spoj B kombinirani unutar pilule.
A product for use as set forth in claim 5 comprising a form which is capable of administration to an individual orally as a liquid, intravenously as a liquid, or by inhalation. 
Proizvod, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što je u obliku kojeg se može primijeniti na osobi oralno u obliku tekućine, intravenski u obliku tekućine ili inhaliranjem.
preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing with ethanol, and filtered to remove impurities; and the ethanol is recovered and concentrated to give #1 Extract for later use; 
Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen de Cassiae se pomiješaju, ekstrahiraju uz refluks i zagrijavanje s etanolom i filtriraju kako bi se uklonili nečistoće; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 1 za kasniju uporabu;
preparation of #2 Extract: Radix Paeoniae alba is extracted by using heating refluxing with ethanol, and filtered; and the ethanol is recovered and concentrated to give #2 Extract for later use; 
priprema ekstrakta br. 2: Radix Paeoniae alba se ekstrahira uz refluks i zagrijavanje s etanolom i filtrira; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 2 za kasniju uporabu;
preparation of #3 Extract: Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Spica Prunellae, Concha Margaritifera Usta and Herba Asari are mixed, decocted with water, filtered, concentrated, into which ethanol is added to leave it to stand still, and filtered; and the ethanol is recovered and concentrated to give #3 Extract for later use; 
Priprema ekstrakta br. 3: Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Špica Prunellae, Concha Margaritifera Usta i Herba Asari se pomiješaju, ukuhavaju vodom, filtriraju, koncentriraju, u koje se dodaje etanol, ostavi stajati i filtrira; i etanol se izdvaja i koncentrira da se dobije ekstrakt br. 3 za kasniju uporabu;
preparation of formulations: aforesaid three Extracts are added with appropriate amount of excipients, dried, and granulated to obtain the final product. 
priprema formulacija: u gore navedena tri ekstrakta dodaje se odgovarajuća količina ekscipijenta, a potom se suše i granuliraju da se dobije konačni produkt.
preparation of formulations: aforesaid three Extracts are added with appropriate amount of excipients, dried, granulated to obtain the final product. 
pripremanje pripravaka: u gore navedena tri ekstrakta dodaje se odgovarajuća količina ekscipijenta, a ekstrakti se potom suše i granuliraju da se dobije konačni produkt.